Clinical trials: Infectious Respiratory Diseases
SARS-CoV Infection
Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis
Protocol summary Title A Prospective, randomized, adaptive phase II/III clinical trial, controlled, open-label, chemoprevention, 3-arms, parallel, multi-centred, to A Prospective, randomized, clinical trial, controlled…
- Trial name
- APCC-19 (NCT04597775)
- Testing
- hydroxychloroquine
- Volunteers
- 93 people
- Sponsor
- Regional Center for Disease Control and Prevention, Jordan
Sars-CoV2
REassessement After Hospitalization for Sars-COV-2 disordER
Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described.
- Trial name
- REHCOVER (NCT04443257)
- Testing
- assessment of the sequelae after hospitalization for Sars-COV-2
- Where
- France
- Volunteers
- 119 people
- Sponsor
- University Hospital, Montpellier
Pneumonia, Lower Respiratory Tract Infection
A Clinical Pathway for Nursing Home Acquired Pneumonia
Nursing home residents are frequently transferred to hospital for management of pneumonia. This often leads to hospital related complications and is a burden on the acute care health system.
- Trial name
- NCT00157612
- Testing
- a clinical pathway nursing home acquired pneumonia
- Volunteers
- 680 people
- Sponsor
- McMaster University
Long COVID, Brain Fog
Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID
The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome. Participants will be given probiotics or placebo capsules for two month.
- Conditions
- Long COVID, Brain Fog, Cognitive Change
- Trial name
- COVID-19 (NCT06348212)
- Testing
- Lactobacillus paracasei PS23, microcrystalline cellulose
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Complication, Postoperative
Perioperative Fluid Management: Goal-directed Versus Restrictive Strategy
There is no ideal "cookbook recipe" for fluid prescription that would fit every surgical patient. In this study, the investigators working hypothesis is that the adoption of an integrative algorithm for perioperative fluid and…
- Trial name
- NCT02625701
- Testing
- Goal-directed therapy, Restrictive fluid therapy
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Geneva
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Ventilator Associated Pneumonia
Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care
Increasing emergence of multidrug resistant (MDR) bacteria worldwide is now considered one of the most urgent threats to global health.
- Trial name
- ASPIC (NCT05124977)
- Testing
- Antimicrobial Stewardship, Standard management
- Where
- France
- Volunteers
- 590 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Corona Virus Infection
A Study of Quintuple Therapy to Treat COVID-19 Infection
This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
- Conditions
- COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2
- Trial name
- HAZDpaC (NCT04334512)
- Testing
- Hydroxychloroquine, Azithromycin, Vitamin C
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- ProgenaBiome
COVID-19
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
This is a national multicentre observational study with retrospective and prospective data collection to assess the time to hospitalisation of patients with a confirmed diagnosis of SARS-CoV-2 infection receiving treatment with…
- Trial name
- CONDIVIDIAMO (NCT05268601)
- Testing
- Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination
- Where
- Italy
- Volunteers
- 251 people
- Sponsor
- University of Milano Bicocca
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Corona Virus Infection, Pneumonia
COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused mass mortality in the last 3 months that necessitates urgent development of new therapeutical agents.
- Trial name
- NCT04389385
- Testing
- COVID-19 Specific T Cell derived exosomes (CSTC-Exo)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- TC Erciyes University
Long COVID
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long…
- Trial name
- NCT07627815
- Testing
- Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations
- Where
- 4 sites in Canada
- Volunteers
- 82 people
- Sponsor
- ParagonClinicals Inc.
PASC Post Acute Sequelae of COVID 19, Long COVID
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that [68Ga]FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging shows potential for diagnosis and molecular…
- Conditions
- PASC Post Acute Sequelae of COVID 19, Long COVID, Long Covid-19, PASC
- Trial name
- LIBERATE (NCT06911476)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
COVID, SARS-CoV 2
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora
Italy was the first European country affected by a severe outbreak of the Severe Acute Respiratory Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic emerged from Wuhan region (China), with a high morbidity and mortality associated…
- Conditions
- COVID, SARS-CoV 2, Pneumonia, Viral, Coronavirus Infection
- Trial name
- PROBIOZOVID (NCT04366089)
- Testing
- Oxygen-ozone therapy, probiotic supplementation and Standard of care, SivoMixx (200 billion), Azithromycin
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Roberto Poscia MD, PhD
COVID-19
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
- Trial name
- MARACOVID (NCT04441385)
- Testing
- Maraviroc 300 mg, Standard care therapy
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Infanta Leonor
Respiratory Infection, Respiratory Infections in Old Age
MeMed BV® Test Evaluation in Adult Emergency Department Patients
The goal of this observational study is to compare the results of a serum biomarker called the MeMed BV®, which is approved to help differentiate between bacterial and viral respiratory infections, to clinical diagnoses of adult…
- Conditions
- Respiratory Infection, Respiratory Infections in Old Age, Respiratory Infection Virus, Respiratory Infection Bacterial
- Trial name
- NCT05706935
- Testing
- MeMed BV® test
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- University of Wisconsin, Madison
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05135650
- Testing
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
COVID-19, SARS-CoV Infection
Glycine Supplement for Severe COVID-19
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in…
- Conditions
- COVID-19, SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia
- Trial name
- NCT04443673
- Testing
- Glycine
- Where
- Mexico
- Volunteers
- 59 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Lung Infection, Pneumonia, Ventilator-Associated
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S.
- Conditions
- Lung Infection, Pneumonia, Ventilator-Associated, Infection, Bacterial, Staphylococcus Aureus
- Trial name
- AR-301-002 (NCT03816956)
- Testing
- AR-301
- Where
- 45 sites in Belarus, Belgium and 13 more
- Volunteers
- 174 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
COVID, COVID19
International SARS-CoV-2 (COVID-19) Infection Observational Study
The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28…
- Conditions
- COVID, COVID19, SARS-CoV 2, Dyspnea
- Trial name
- ICOS (NCT04385251)
- Testing
- Data Collection
- Where
- 4 sites in United States, Argentina and 2 more
- Volunteers
- 11,973 people
- Sponsor
- University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.